These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Nuclear medicine imaging in dementia: a practical overview for hospitalists. Toney LK; McCue TJ; Minoshima S; Lewis DH Hosp Pract (1995); 2011 Aug; 39(3):149-60. PubMed ID: 21881402 [TBL] [Abstract][Full Text] [Related]
29. Inflammation and anti-inflammatory strategies for Alzheimer's disease--a mini-review. McNaull BB; Todd S; McGuinness B; Passmore AP Gerontology; 2010; 56(1):3-14. PubMed ID: 19752507 [TBL] [Abstract][Full Text] [Related]
30. Imaging discrepancies between magnetic resonance imaging and brain perfusion single-photon emission computed tomography in the diagnosis of Alzheimer's disease, and verification with amyloid positron emission tomography. Yokoyama S; Kajiya Y; Yoshinaga T; Tani A; Hirano H Psychogeriatrics; 2014 Jun; 14(2):110-7. PubMed ID: 24954834 [TBL] [Abstract][Full Text] [Related]
31. The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease. Minter MR; Taylor JM; Crack PJ J Neurochem; 2016 Feb; 136(3):457-74. PubMed ID: 26509334 [TBL] [Abstract][Full Text] [Related]
32. The emerging role of PET imaging in dementia. Iaccarino L; Sala A; Caminiti SP; Perani D F1000Res; 2017; 6():1830. PubMed ID: 29071066 [TBL] [Abstract][Full Text] [Related]
33. Neuroimaging as a diagnostic tool in dementia with Lewy bodies. Small GW Dement Geriatr Cogn Disord; 2004; 17 Suppl 1():25-31. PubMed ID: 14676466 [TBL] [Abstract][Full Text] [Related]
34. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC; Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725 [TBL] [Abstract][Full Text] [Related]
35. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126 [TBL] [Abstract][Full Text] [Related]
36. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW; Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191 [TBL] [Abstract][Full Text] [Related]
37. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. Rodriguez-Vieitez E; Saint-Aubert L; Carter SF; Almkvist O; Farid K; Schöll M; Chiotis K; Thordardottir S; Graff C; Wall A; Långström B; Nordberg A Brain; 2016 Mar; 139(Pt 3):922-36. PubMed ID: 26813969 [TBL] [Abstract][Full Text] [Related]
38. What can imaging tell us about cognitive impairment and dementia? Narayanan L; Murray AD World J Radiol; 2016 Mar; 8(3):240-54. PubMed ID: 27029053 [TBL] [Abstract][Full Text] [Related]
39. Combination therapy for Alzheimer's disease and related dementias. Bednar MM Prog Mol Biol Transl Sci; 2019; 168():289-296. PubMed ID: 31699322 [TBL] [Abstract][Full Text] [Related]
40. Neuroinflammation: A Potential Risk for Dementia. Ahmad MA; Kareem O; Khushtar M; Akbar M; Haque MR; Iqubal A; Haider MF; Pottoo FH; Abdulla FS; Al-Haidar MB; Alhajri N Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054805 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]